Insiders Are Aggressively Buying CURO Group and 2 Other Stocks Under $3 – CURO Group Holdings (NYSE:CURO), HOOKIPA Pharma (NASDAQ:HOOK)

The Dow Jones closed down more than 100 points on Wednesday. When insiders buy or sell shares, it indicates their belief in or concern for the company’s prospects. Investors and traders interested in penny stocks may consider this as a factor in their overall investment or trading decision.

Below is a look at some recent notable insider trading for penny stocks. For more information see Benzinga’s insider trading platform.

CURO Group Holdings

• Business: CURO Group Holdings Corp. curo CEO Douglas Clarke Total 20,000 shares acquired Average price of $1.39. It cost about $27,844 to acquire these shares.
• What are you saying: Stephens & Company recently reiterated CURO Group Holdings to Equal-Weight and maintained a $3 price target.
• What CURO Group Holdings does: CURO Group Holdings Corp. is a consumer finance company serving a full spectrum of non-prime, near-prime and prime consumers in the United States and parts of Canada.

Huqipa Pharma

• Business, Huqipa Pharma Inc. hook CEO Jorn Eldag Total 5,000 shares acquired At an average price of $0.89. The Insider spent approximately $4,456.
• What are you saying?: RBC Capital recently reiterated HOOKIPA Pharma with Outperform and maintains a $7 price target.
• what does hookipa pharma do: HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform designed to reprogram the body’s immune system .

Fio Pharmaceuticals

• Business, Feo Pharmaceuticals Corporation fio President and CEO Robert Bitterman Total 2,000 shares acquired At an average price of $2.86. It cost about $5,720 to acquire these shares.
• What are you saying?: Fio Pharmaceuticals recently announced a $4 million concurrent registered direct offering and private placement at market value under Nasdaq regulations.
• what does fio pharmaceuticals doFio Pharmaceuticals Corp. is a US-based biotechnology company. It is primarily engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, that address critical unmet medical needs.

Check it out: Investor optimism improved slightly after Fed minutes

don’t forget to check out our premarket coverage here